Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling

Primary Disease Clinical Trial

Official title:

Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling/Hydroxyapatite Nanoparticles--Comparisons Between Non-viral and Viral Administration in Tissue Engineered Bone Regeneration

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01323894
• Other study ID #: ?DMR-99-IRB-122
• Status: Completed
• Phase: N/A
• First received: March 24, 2011
• Last updated: June 15, 2016
• Start date: August 2011
• Est. completion date: July 2013

Study information

• Verified date: June 2016
• Source: China Medical University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Department of Health
• Study type: Observational

Clinical Trial Summary

The first year purpose:

The best concentration of canonical Wnt3a will be investigated in promoting the osteoblastogenesis of human mesenchymal stem cells.

Description:

Our previous work is investigating the viral (Adv-BMP-2) administration for the development of a model to generate bones for possible use in clinical settings; the non-viral and viral administrations will be compared for best osteogenesis effects.

The first year purpose:

The best concentration of canonical Wnt3a will be investigated in promoting the osteoblastogenesis of human mesenchymal stem cells.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3
• Est. completion date: July 2013
• Est. primary completion date: August 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 10 Years to 80 Years

Eligibility

Inclusion Criteria:

• age above 10 years old

• The patients require surgery ner iliac or abdomen areas

Exclusion Criteria:

• age below 10 years old

Study Design

N/A

Related Conditions & MeSH terms

• Primary Disease

Locations

Country	Name	City	State
Taiwan	China Medical Universty Hospital	Taichung

Sponsors (1)

Lead Sponsor	Collaborator
China Medical University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling/Hydroxyapatite Nanoparticles--Comparisons between Non-viral and Viral administration in Tissue Engineered Bone Regeneration	August 2011-July 2013	2 years	No